The ongoing clinical trial research report- “2019 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Ongoing Clinical Trials Study” analyzes the current scenario of all active Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer trials across the world. The report presents top level analysis of global Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer clinical trials across countries, companies and universities. It is designed to provide clear understanding into the Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer trials landscape to assist users for effective long term strategy formulation to beat competition.
The report covers a key snapshot of ongoing trial count, average enrollment per trial across countries.
It also segments the Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer clinical trials by- • Region (Asia Pacific, Europe, Middle East Africa and Americas) • Countries • Trial Phase • Current Trial Status (Recruiting, Active, Planned, Active but Completed Recruiting, Not Yet Recruiting etc) • Type of the trial (Interventional, Observational) • Sponsor Type (Companies, Universities, Government Bodies etc) • Enrollment across types, sponsor types, geographies, current status and phases
The report also identifies the potential drug candidates under development for treatment of Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer on the basis of intervention type ongoing Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer trials.
The research work is prepared through extensive and continuous research on Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer trials from over 150 sources including company websites, conferences and presentations, scientific journals, country wise and global clinical trial registries, news, health and science departments among others.
Report Scope and Coverage: • All major ongoing trials from 2010 to 2019 and planned trials are included in the report scope. • Drug candidates currently being researched for administering Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer patients are identified • The report includes panorama of ongoing Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer clinical trials across the globe • Trial Phase, Current Status, Sponsor Type, Location, trial type and Enrollment details are provided • Companies and universities focusing on Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer clinical trials are analyzed along with their trial participation (trial title, trial phase and current status) • Average Enrollment number, insights into enrollment trends, company wise enrollment are included • Both interventional and observational studies are analyzed • News and latest developments for the past one year are presented in the report
Our reports have been used by over 10K customers, including:
Colorectal Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2020
Summary
Medical Devices sector report, “Colorectal Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2020" provides comprehensive information about the Colorectal Cancer Diagnostic Tests pipeline products...
143 pages •
By Transparency Market Research
• Nov 2020
Electron Beam Linear Accelerators Market – Scope of the Report This report on the global electron beam linear accelerators market studies the past as well as current growth trends and opportunities to gain valuable insights of these indicators for the market during the forecast period from 2020 to 2030.The report provides...
Summary Veracyte Inc (Veracyte) is a molecular diagnostics company that uses genomic technology to resolve diagnostic ambiguity.The company’s pipeline products comprise Afirma thyroid FNA analysis for the diagnosis of thyroid cancer based on its proprietary afirma gene expression classifier. It also provides percepta...
172 pages •
By Global Industry Analysts
• Apr 2021
Abstract:
- Global Myeloproliferative Disorders Drugs Market to Reach $9.9 Billion by 2027
- Amid the COVID-19 crisis, the global market for Myeloproliferative Disorders Drugs estimated at US$7.8 Billion in the year 2020, is projected to reach a revised size of US$9.9 Billion by 2027, growing at aCAGR of 3.4% over...
Fallopian Tube Cancer Market Report Overview Fallopian Tube Cancer market size outlook report provides comprehensive coverage of market landscape including strategic growth areas, unique insights, and major trends across Fallopian Tube Cancer market types and applications. It is a focused study on Fallopian Tube Cancer market space including...
“XmAb14045 - Emerging Insight and Market Forecast - 2030” the report provides comprehensive insights about an investigational product for Blastic Plasmacytoid Dendritic Cell Neoplasm in 7 Major Markets. A detailed picture of the XmAb14045 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom),...
426 pages •
By Roots Analysis Private Ltd.
• Nov 2020
INTRODUCTION Since the success of ADCETRIS® (approved in 2011), antibody drug conjugates (ADCs) are now considered a versatile therapeutic tool and have been accepted into the contemporary portfolio of mainstream healthcare solutions. Over time, clinical researchers have been able to further their understanding of the intricacies...
The alpha emitter market is expected to witness a healthy CAGR of 36.7% during the forecast period (2020 - 2025). Certain factors that are driving the market growth include increased awareness about the potential benefits of targeted alpha therapy and the growing number of patients with cardiac and cancer ailments. Targeted anticancer...